ODYSSEY GROUP INTL INC - ODYY STOCK NEWS

Odyssey Health, Inc. (OTC: ODYY) provided a company update, emphasizing progress in developing life-enhancing medical products. The highlight is a successful Phase I clinical trial for a concussion drug, with preparations for Phase II underway. The global concussion treatment market, valued at $6.9 billion in 2020, is expected to grow to $8.9 billion by 2027. Odyssey also announced plans for a nerve agent antidote, a choking rescue device, and a rapid EKG tool, while raising over $5 million and reducing share dilution.

Odyssey Health, Inc. (OTC: ODYY) provides a significant update on its concussion drug development program, which addresses a global medical need. Since acquiring the drug's rights in March 2021, the company has made notable advancements, including:

• Completion of a Phase I clinical trial proving safety and tolerability.
• Development of a novel breath-propelled intranasal delivery device.
• Raised over $5 million to support ongoing efforts and secured access to an equity line of up to $10 million.

Odyssey aims to transform concussion treatment with its synthetic neurosteroid.

Odyssey Health, Inc. (OTC: ODYY) will hold its Annual Meeting of Stockholders on January 12, 2023. To participate, stockholder proposals must be submitted by November 25, 2022, to the corporate offices in Las Vegas. The proposals should comply with company bylaws. Odyssey is focused on developing unique medical products and solutions with significant market potential. The company emphasizes creating and acquiring distinct assets and technologies that enhance clinical utility.

Odyssey Health, Inc. (OTC: ODYY) is strengthening its commitment to Odyssey NeuroPharma with key executive appointments, including Erik Emerson as Chief Commercial Officer and Greg Gironda as Chief Operating Officer. Both executives bring over 50 years of combined experience in the pharmaceutical sector. Odyssey NeuroPharma aims to address unmet medical needs in traumatic brain injury, planning a Phase II clinical trial to evaluate treatment efficacy. Currently, no FDA-approved treatments exist for concussions, which affect over 5 million people in the U.S. annually.

Odyssey Health, Inc. (OTC: ODYY) has filed for patent protection for its innovative intranasal brain-drug delivery device, designed to treat concussions. The recently completed Phase I study confirmed the safety and effectiveness of using this device with Odyssey's concussion drug, PRV-002, on 40 healthy volunteers. The study observed no device failures, indicating strong performance. This technology aims to enhance drug delivery for central nervous system conditions, potentially leading to significant market opportunities in the healthcare sector.

Odyssey Health (OTC: ODYY) has launched Odyssey Neuropharma, its new subsidiary dedicated to developing drugs targeting neurological disorders. The company aims to overcome the blood-brain barrier with an innovative intranasal delivery device, improving drug efficiency and reducing side effects. Planned products include treatments for concussion, Niemann-Pick type C disease, and a nerve agent antidote. Previous studies highlight the promising efficacy of the intranasal method, suggesting targeted brain delivery with minimal systemic absorption.

Odyssey Health (OTC: ODYY) has made significant advancements in its concussion drug development program. The company successfully completed a Phase I clinical trial for its drug, PRV-002, which is designed to treat concussions by rapidly crossing the blood-brain barrier. Key achievements include the completion of pre-clinical toxicology studies, development of a proprietary intranasal delivery device, and obtaining ethical approval for trials. The global concussion treatment market, valued at $6.9 billion in 2020, is projected to reach $8.9 billion by 2027, indicating substantial growth potential.

Odyssey Health (OTC: ODYY) announced the dissolution of its sports advisory board aimed at concussion awareness to focus on its drug development efforts. The company has completed a Phase I trial of its concussion treatment drug, PRV-002, showing safety and tolerability. There are plans for a Phase II trial to assess efficacy in concussed patients. The company clarified that it has not received government funding and is not involved in litigation. Funding for the drug's development has come from accredited investors since acquiring the drug rights on March 1, 2021.

Odyssey Health (OTC: ODYY) has completed all cohorts of its Phase I clinical trial for PRV-002, a novel drug designed to treat concussion. Conducted on 40 healthy volunteers, the trial demonstrated that PRV-002 was safe and well tolerated, with no severe adverse events reported. The trial analyzed both Single Ascending Dosing (SAD) and Multiple Ascending Dosing (MAD) and showed a direct linear relationship between drug dosing concentration and plasma levels. Results indicate potential for greater delivery to the brain, supporting further clinical trials for concussion patients.